Potentiation of the Thrombolytic Efficacy of Single-Chain Urokinase (Pro-Urokinase) by Heparin

D C Gulba; K Fischer; G H Reil; W G Daniel; P R Lichtlen

doi:10.1055/s-0038-1647064

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 60(02): 350-351
DOI: 10.1055/s-0038-1647064

Letter to the Editor

Schattauer GmbH Stuttgart

Potentiation of the Thrombolytic Efficacy of Single-Chain Urokinase (Pro-Urokinase) by Heparin

D C Gulba

Hannover Medical School, Dept, Cardiology, Hannover, West Germany

,

K Fischer

Hannover Medical School, Dept, Cardiology, Hannover, West Germany

,

G H Reil

Hannover Medical School, Dept, Cardiology, Hannover, West Germany

,

W G Daniel

Hannover Medical School, Dept, Cardiology, Hannover, West Germany

,

P R Lichtlen

Hannover Medical School, Dept, Cardiology, Hannover, West Germany

› Author Affiliations

Abstract

PDF Download

PDF (316 kb)

References

References
1 Gruppo Italiano per Studio Streptochinasi nell’Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarctio. Lancet 1986; 1: 397-401
2 Simoons ML, vd Brand M, De ZwaanC, Verheugt FWA, Remme WJ, Serruvs PW, Bar F, Res J, Krauss XH, Vermeer F, Lubsen J. Improved survival after early thrombolysis in acute myocardial infarction - A randomized trial by the Interuniversity Cardiology Institute of theNetherlands. Lancet 1985; 2: 578-581
3 Topol EJ, Califf RM, George BS, Kereiakes DJ, Abottsmith CW, Candella RJ, Lee KL, Pitt B, Stack RS. O’Neill W W and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue type plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-588
4 Sheehan F, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO. Zaret B and Co-Investigators. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and strepto-kinase from the thrombolysis in myocardial infarction (TIMI Phase I) Trial. Circulation 1987; 75: 817-829
5 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (Pro-urokinase) - A Study in Vitro and in Two Animal Species. J Clin Invest 1984; 73: 1731-1739
6 Gulba D, Reil G-H, Zwicky R, Peters S, Liehtlen P. suppl. 18 (Abstr) Thrombolytic therapy in acute myocardial infarction using Pro-urokinase (PUK) - Positive Effect of a Low Dose Urokinase (UK) Preactivation. Haemostasis 1988; 2: 140
7 Lijnen HR, Collen D. Stimulation by heparin of the plasminmediated conversion of single-chain to two-chain urokinase-type plasminogen activator. Thromb Res 1986; 43: 687-690
8 Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Colien D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase type plasminogen activator. Thromb Haemostas 1987; 58: 947-950
9 Ichinose A, Spores J, Nortske R, Mouser LT, Burroghs R, Golden MS, Lang HT. The activation of Pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-3489
10 Gurewich V, Panell R. Inactivation of single-chain urokinase (Prourokinase) by thrombin and thrombin-like enzymes. Relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769-772